Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
LOKELMA® (sodium zirconium cyclosilicate) is indicated for the treatment of hyperkalaemia in adult patients.
Looking to update your local guidelines?
Access an evidence-based summary to support formulary changes and guideline development in your area.
Interested in optimising RAASi therapy whilst managing hyperkalaemia?
A practical toolkit to help optimise RAASi therapy and manage hyperkalaemia, including a sample discharge summary, transfer of care letter, and guidance for optimising RAASi therapy in cardiorenal patients.
How to prescribe LOKELMA
Quick-reference guide outlining LOKELMA administration and dosing for both non-haemodialysis and dialysis patients.
LOKELMA maintenance prescribing protocol for community prescribing
Your step-by-step guide to continuing LOKELMA in the community, supporting patients to stay on guideline-directed RAASi therapy
Act from 5.5mmol/L to raise the bar for your cardiorenal patients
A5 booklet summarising the updated NICE tag for LOKELMA and why intervening from serum K+ 5.5mmol/L matters for your eligible patients
Patient guide: LOKELMA & hyperkalaemia
Patient leaflet explaining hyperkalaemia, what LOKELMA is, and what patients can expect from treatment.
Patient guide: protecting your heart & kidneys
Helps patients understand their RAASi therapy and how it works alongside LOKELMA to support long-term heart and kidney health.
Videos and webinars
Learn more from the experts about the importance of RAASi optimisation in cardiorenal (HF or CKD) patients with hyperkalaemia
RAASi=renin-angiotensin-aldosterone system inhibitor; KDIGO=Kidney Disease: Improving Global Outcomes; CKD=chronic kidney disease; ESC=European Society of Cardiology; HF=heart failure.
GB-71496 | October 2025
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
GB-74216| DOP : February 2026
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
